(Q37858364)

24 August 2017

1 reference

title

Incretin therapies in the management of elderly patients with type 2 diabetes mellitus (English)

1 reference

Isabelle Bourdel-Marchasson

24 August 2017

0 references

0 references

series ordinal

1

object named as

Isabelle Bourdel-Marchasson

1 reference

24 August 2017

Anja Schweizer

2

1 reference

24 August 2017

Sylvie Dejager

series ordinal

3

1 reference

24 August 2017

language of work or name

English

0 references

publication date

1 February 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

39

1 reference

24 August 2017

issue

1

1 reference

24 August 2017

page(s)

7-21

1 reference

The growing burden of diabetes mellitus in the US elderly population.

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

The burden and treatment of diabetes in elderly individuals in the u.s.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

Antidiabetic oral treatment in older people: does frailty matter?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

Key priorities in managing glucose control in older people with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

Hypoglycaemia in Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

Hypoglycaemia in elderly patients with diabetes mellitus: causes and strategies for prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

New approaches to treating type 2 diabetes mellitus in the elderly: role of incretin therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

Unreliability of reports of hypoglycaemia by diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

A critical review of the literature on fear of hypoglycemia in diabetes: Implications for diabetes management and patient education

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

Hypoglycemia unawareness in older compared with middle-aged patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

Avoiding hypoglycaemia while achieving good glycaemic control in type 2 diabetes through optimal use of oral agent therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

A Population-based Study of the Incidence of Complications Associated with Type 2 Diabetes in the Elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

Mortality in older people with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

Type 2 diabetes and risk for functional decline and disability in older persons.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

Association of diabetes, comorbidities, and A1C with functional disability in older adults: results from the National Health and Nutrition Examination Survey (NHANES), 1999-2006

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

Accelerated loss of skeletal muscle strength in older adults with type 2 diabetes: the health, aging, and body composition study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

Cognitive dysfunction is associated with poor diabetes control in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

Changes in cognitive abilities over a 4-year period are unfavorably affected in elderly diabetic subjects: results of the Epidemiology of Vascular Aging Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

Neurocognitive impairment and comorbid depression in patients of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

10-year follow-up of intensive glucose control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

Improving metabolic control leads to better working memory in adults with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

Contraindications can damage your health--is metformin a case in point?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

Metformin, heart failure, and lactic acidosis: is metformin absolutely contraindicated?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

Metformin and cancer: licence to heal?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

Acarbose in the treatment of elderly patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

Glitazone use associated with diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

Thiazolidinedione use and bone loss in older diabetic adults

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

Varying insulin use in older hospitalized patients with diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

Severe hypoglycemia in critically ill patients: risk factors and outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

Deconvolution analysis of rapid insulin pulses before and after six weeks of continuous subcutaneous administration of glucagon-like peptide-1 in elderly patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

Effects of 3 Months of Continuous Subcutaneous Administration of Glucagon-Like Peptide 1 in Elderly Patients With Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

Benefit-risk assessment of exenatide in the therapy of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

Liraglutide: a review of its use in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

Sitagliptin: a review of its use in the management of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

Vildagliptin: a review of its use in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥75 years: a pooled analysis from a database of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

Efficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes and mild hyperglycaemia*.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

Saxagliptin in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

Pharmacokinetics of dipeptidylpeptidase-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

Alogliptin: a review of its use in the management of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2011.02.369

21 January 2018

Identifiers

DOI

10.3810/HP.2011.02.369

1 reference

24 August 2017

1 reference